Welcome to Nanjing MeiRui Pharma Co., Ltd.
Nanjing MeiRui Pharma Co., Ltd., (MeiRui) is an Chinese ethical pharmaceutical company specializing in products to treat and diagnose urological conditions. MeiRui is one of the leaders in therapeutics for the treatment of BPH and Overactive Bladder, and is constantly expanding its product offerings to treat and diagnose related conditions. The Company works closely with the Chinese Urological Association to develop enhanced standards for the treatment of urological diseases and new therapies for their care. MeiRui is the China operating entity of Pagoda Pharma Group. Click HERE for more information about Pagoda.

MeiRui Communication is a quarterly publication focusing on advances in urology treatment and diagnosis. The publication provides a forum for leading urologists to present their latest ideas and research and encourages communication among urologist throughout China. As Professor Na, the former President of the Chinese Urology Association and the head of Urology Research Institute, Beijing University said in the foreword to first issue of MeiRui Communication, it will improve the mutual understanding and cooperation between departments and urologists, and will promote the development in urology area in China.

The following are summaries of MeiRui Communication. In each summary their is a link where you can download the entire volume. Most of the text in MeiRui Communication is in Chinese.

MeiRui Communications, Vol. 1, 2009: This issue presented findings and papers from the 7th MeiRui 21st Century Forum for Urologists. The Forum included many of the leading urologist in China, including Prof. Na, the outgoing president of the Chinese Urological Association and Prof. Yi, the incoming president. The presentations focused on the latest therapies for the treatment of BPH and Prostatitis, and the potential for anti-inflammatory agents, like Prostat, to be used in the very early stages of the development of BPH. (LINK TO MEIRUI COMMUNICATIONS VOL. 1, 2009)

MeiRui Communications, Vol. 2, 2009: This issue discussed four recent articles regarding the inflammatory processes in prostate and surrounding tissues and their relationship to BPH and Prostatitis. Discussions were lead by Professor Tingyi Bao and Professor Jiansong Wang, both heads major urology departments.
(LINK TO MEIRUI COMMUNICATIONS VOL. 2, 2009)

MeiRui Communications, Vol. 3, 2009: Nine urology thought leaders introduced and discussed the latest advancements in Urology. Topics included overactive bladder (OAB) and its treatment, treatment of BPH in patients with OAB and new protocols in the treatment of neurogenic OAB. (LINK TO MEIRUI COMMUNICATIONS VOL. 3, 2009)

MeiRui Communications, Vol. 4, 2009: This volume focused on the latest treatments for various conditions leading to urinary incontinence in women. Seven leading urologists lead these discussions.
(LINK TO MEIRUI COMMUNICATIONS VOL. 4, 2009)


Our Mission
MeiRui's mission is to provide people suffering from diseases with the best products and services available. The Company constantly strives to improve its ability to offer innovative products and to make sure they are delivered to those in need.

Our Goal
MeiRui's goal is to be a leading Chinese pharmaceutical and diagnostic company in the field of urology, and to constantly add new products that treat conditions affecting the elderly. Meirui's Goal is also to always act with compassion, caring and understanding in improving the health and well being of the Chinese people.

MeiRui's Major Products

The following are the general description of the major MeiRui products. Also shown is the Clinical Handbook. At the end of each product description is a link to additional information for patients and doctors. On those pages are product inserts, product brochures and other documents for both doctors or patients. Those documents are written in Chinese, as you would expect.

General Information: MeiRui Pharma Clinical Handbook

Prostat is a treatment for Benign prostatic hyperplasia (BPH) and chronic non-bacteria prostatitis, the most common urinary diseases among mature men. Prostat is an effective BPH therapy with low adverse effects. Prostat is also the only approved therapy for prostatitis, a difficult to treat condition, almost as common as BPH. Recent scientific findings indicate that Prostat's anti-inflammatory action may actually slow the onset of BPH and therefore be an effective prophylactic for the onset for that condition. Read more about the anti-inflammatory treatment of BPH in MeiRui Communications 2009 Vol. 1 (see above)..
Click here for more information about Prostat.

SheNiTing (Tolterodine) is indicated for the treatment of patients with overactive bladder (OAB). OAB is a condition where you have frequent and strong urges to go to the bathroom (urinate). This condition affects a large percentage of mature women and some men. In men, OAB can be associated with BPH. OAB can be an embarrassing condition that can have dramatic affects on the quality of day to day life. SheNiTing acts by calming and controlling frequent contractions of the bladder muscle, the cause of the urge to urinate.
Setrole is MeiRui's once a day version of its OAB therapeutic. Click here for more information about SheNiTing and Setrole.

Urexact is digital urine monitoring system used for to measure the urine output of intensive care patients. Urexact is a next generation system that is much more precise then existing urine collection bags. In addition, Urexact gives advance information on kidney function and may allow for the early detection of kidney distress or kidney failure, a very common occurrence in critically ill patients. Click here for more information about Urexact.

ImmunoCAP is a complete automated system of instrumentation, software and reagents to determine the type and quantity of hundreds of allergen producing antibodies. The ImmunoCAP system is manufactured by Phadia, the world's leader in immuno-diagnostic automated systems. The ImmunoCAP system allows physicians to determine the exact cause or causes of the allergies and asthma that affect a high percentage of the population. ImmunoCAP uses a small blood sample to determine which allergen antibodies (IgE, IgG and IgA) are present, and to determine the quantity of each of these antibodies. Click here for more information about ImmunoCAP and Allergy products.
Text Size A A A
 Login
Meirui Intranet
 Quick Links
CUA/CUAN News
Pharmaceutical Products
Allergy Products
New Products Department
 
 
  Home | Careers | Contact Us | Privacy Policy | Sitemap | Terms of Use